Induction and drug development

Area of Science:

• Pharmacology
• Drug Metabolism
• Medicinal Chemistry

Background:

• Enzyme induction is an undesirable drug interaction that impacts co-administered drug efficacy, not safety.
• While many drugs have induction potential pre-clinically, this rarely translates to clinical situations.
• Current screening methods using human hepatocytes are limited by supply and response variability.

Purpose of the Study:

• To explore the factors influencing clinical enzyme induction, particularly cytochrome P450 (CYP) induction.
• To investigate the relationship between drug dose, potency, and the potential for enzyme induction.
• To provide guidance for drug discovery and development programs to mitigate enzyme induction risks.

Main Methods:

• Analysis of clinical data on known enzyme inducers and non-inducers.
• Review of pre-clinical screening data and limitations.
• Examination of drug properties, including lipophilicity (LogP) and dose size.
• Case study comparison of troglitzone and rosiglitazone.

Main Results:

• The major inducible cytochrome P450 enzyme in humans is CYP3A4.
• Clinically significant CYP3A4 induction is primarily associated with drugs administered at high daily doses.
• Lower doses of more potent drugs, like rosiglitazone, can avoid CYP3A4 induction seen with less potent analogues like troglitzone.
• Lipophilicity is a general characteristic of enzyme inducers, but no specific structure-activity relationships are evident from clinical data.

Conclusions:

• Drug dose size is a critical factor in clinical enzyme induction, especially for CYP3A4.
• Adhering to "Golden Rules" of drug design, focusing on moderate daily dose size and target potency, can minimize enzyme induction.
• Optimizing pharmacokinetics and potency allows for lower therapeutic doses, reducing the risk of undesirable drug interactions.